This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
InnovAge Holding Corp. (INNV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of 0% and 4.07%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
InnovAge Holding Corp. (INNV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -100% and 3.21%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
InnovAge Holding Corp. (INNV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -200% and 1.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
InnovAge Holding Corp. (INNV) Soars 15.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
InnovAge Holding Corp. (INNV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
HealthEquity (HQY) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 12.77% and 1.95%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
LumiraDx Limited (LMDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
LumiraDx Limited (LMDX) delivered earnings and revenue surprises of -6.67% and 0.31%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
MDxHealth SA Sponsored ADR (MDXH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MDxHealth SA Sponsored ADR (MDXH) delivered earnings and revenue surprises of 6.25% and 10.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Hold on to Teladoc Health (TDOC) Stock for Now?
by Zacks Equity Research
Teladoc Health's (TDOC) cash-generating abilities are boosted by the growing number of visits and memberships.
InnovAge Holding Corp. (INNV) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of 0% and 1.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
3 Medical Services Stocks to Buy Amid Industry Challenges
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. EMBC, INNV and OCX are set to gain the most. However, staffing shortages may disrupt the trend.
InnovAge Holding Corp. (INNV) Loses -7.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for InnovAge Holding Corp. (INNV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
InnovAge Holding Corp. (INNV) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of 36.36% and 1.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
InnovAge Holding Corp. (INNV) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -150% and 1.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Agilon Health (AGL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agilon (AGL) delivered earnings and revenue surprises of -40% and 6.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Doximity (DOCS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Doximity (DOCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: InnovAge Holding Corp. (INNV) Q1 Earnings Expected to Decline
by Zacks Equity Research
InnovAge Holding Corp. (INNV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights InnovAge Holding, Spirit AeroSystems Holdings, Tandem Diabetes Care and HCI Group
by Zacks Equity Research
InnovAge Holding, Spirit AeroSystems Holdings, Tandem Diabetes Care and HCI Group have been highlighted in this Screen of The Week article.
4 Toxic Stocks That May Risk Your Peace and Prosperity
by Rimmi Singhi
Stocks like INVV, SPR, TNDM and HCI could prove hazardous for your portfolio. So, it's best to dump these toxic stocks, especially amid the prevailing market mayhem.
InnovAge Holding Corp. (INNV) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -200% and 0.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for InnovAge (INNV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to InnovAge (INNV) stock based on the movements in the options market lately.
Zacks.com featured highlights include Madison Square Garden Entertainment, Materialise, InnovAge Holding, and Ligand Pharmaceuticals
by Zacks Equity Research
Madison Square Garden Entertainment, Materialise, InnovAge Holding, and Ligand Pharmaceuticals are part of zacks screen of the week article.
Detoxify Your Holdings by Steering Clear of These 4 Stocks
by Rimmi Singhi
Getting rid of fundamentally weak toxic stocks is important to shield your portfolio from losses. MSGE, MTLS, INNV and LGND are a few toxic stocks according to our model that you should dump now.
InnovAge Holding Corp. (INNV) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -300% and 5.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 42.86% and 8.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -225% and 1%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?